PharmaMar, leaders in the development of a new generation of marine-derived drugs

 
Founded in 1986, PharmaMar, a wholly owned member of the Zeltia Group, is a biopharmaceutical company determined to advance cancer treatment through discovering, developing, producing, and marketing innovative drugs of marine origin.
 
The company has a unique marine organism library containing over 115,000 specimens. PharmaMar’s Research, Development, and Innovation Department has discovered 700 new chemical entities and identified 30 new families of compounds. As a result of this work, PharmaMar has over 1800 patents that either have been awarded or are in the processing stage.
 
PharmaMar ranks among the leading Spanish pharmaceutical companies that invest heavily in Research, Development, and Innovation. During its first 20 years it has devoted 470 million euros to R+D+i.
 
At its head office in Colmenar Viejo (Madrid), the company has a workforce of highly qualified professionals who specialize in the pharmaceutical sector. Seventy percent are university graduates and, of these, 60% are doctors. PharmaMar’s employees are part of a global network of excellence, in which over 60 research centres and universities worldwide collaborate to find new discoveries in marine biology, chemistry, and cancer biology.
 
Over 12,000 patients with different types of cancer, at over 200 hospitals worldwide, have benefited from treatment with PharmaMar's compounds.

 

At our facilities in Colmenar, we synthesize intermediates and active principles (APIs) for the manufacture of our drugs, and undertake secondary conditioning to meet the commercial demand and needs of our products for clinical trials already under way and compassionate use programmes. We do this with the levels of service, agility and rigour that these activities require to guarantee industrialscale manufacture and supply of our products, always in strict compliance with Good Manufacturing Practices (GMP) and the regulations on protecting our workers and the environment.

 

Clinical development is accompanied by the development of products, processes and analytical methods. This allows for continuous improvement and ensures the quality of our products, while complying with the regulatory requirements for the authorisation of our clinical trials.

 

This arduous systematic work enables us to define a solid validated industrial process, culminating with the chemical and pharmaceutical documentation required by the authorities to authorise our products for commercialisation.

 

 

Our spirit, tenacity and desire to meet the needs of our patients and health professionals has led us to take on the European market, i.e. over 450 million people with varied national legislation and more than 20 official languages.

 

PharmaMar has a specialised sales team for the commercialisation in Europe. Sales in the big Western European countries are covered by a sales network established for PharmaMar under an agreement with Quintiles Group organised in nine territories. In the rest of Europe, promotional and sales distribution agreements have been signed with Swedish Orphan Biovitrum for the Nordic countries and Eastern Europe, and with Genesis Pharma for Greece, Cyprus and the Balkan region